Anna Varghese

Featured in: Favicon

jamanetwork.com (+1) Favicon

thehindu.com Favicon

ascopubs.org Favicon

cancertreatmentreviews.com Favicon

destinationsmagazine.com Favicon

Articles

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. | Journal of Cli

May 31, 2023 | ascopubs.org | Catherine O'Connor |Joanne F. Chou |Carly Schwartz |Anna Varghese

Background: Maintenance olaparib improves PFS in gBRCA1/2m (core HRD) in mPDAC (Golan, NEJM 2019). Whether other HRD indicators, such as gene mutations other than gBRCA1/2m (non-Core HRD, Cohort B) and exceptional platinum responders (Cohort C, response > 6 months) may benefit from PARPi in mPDAC remains unanswered. We hypothesized that pembrolizumab and olaparib (POLAR) combination may improve outcome by immunogenic cell death.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →